Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Hidden 'risk' in polygenic scores: clinical use today could exacerbate health disparities

View ORCID ProfileAlicia R Martin, Masahiro Kanai, Yoichiro Kamatani, Yukinori Okada, Benjamin M Neale, Mark J Daly
doi: https://doi.org/10.1101/441261
Alicia R Martin
Broad Institute & MGH;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alicia R Martin
  • For correspondence: armartin@broadinstitute.org
Masahiro Kanai
Broad Institute, MGH, Harvard Medical School, & RIKEN;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoichiro Kamatani
RIKEN & Kyoto University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukinori Okada
RIKEN & Osaka University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin M Neale
Broad Institute & MGH;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J Daly
Broad Institute, MGH, & FIMM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

Polygenic risk scores have the potential to improve health outcomes for a variety of complex diseases and are poised for clinical translation, driven by the low cost of genotyping (<$50 per person), the ability to predict genetic risk of many diseases with a single test, and the dramatically increasing scale and power of genetic studies that aid prediction accuracy. However, the major ethical and scientific challenge surrounding clinical implementation is the observation that they are currently of far greater predictive value in individuals of recent European ancestry than others. The better performance of such risk scores in European populations is an inescapable consequence of the heavily biased makeup of genome-wide association studies, with an estimated 79% of participants in all existing genetic studies being of European descent. Empirically, polygenic risk scores perform far better in European populations, with prediction accuracy reduced by approximately 2- to 5-fold in East Asian and African American populations, respectively. This highlights that--unlike specific clinical biomarkers and prescription drugs, which may individually work better in some populations but do not ubiquitously perform far better in European populations--clinical uses of prediction today would systematically afford greater improvement to European populations. Early diversifying efforts, however, show promise in levelling this vast imbalance, even when non-European sample sizes are considerably smaller than the best-powered studies to date. Polygenic risk scores provide a new opportunity to improve health outcomes for many diseases in all populations, but to realize this full potential equitably, we must prioritize greater inclusivity of diverse study participants in genetic studies and open access to resulting summary statistics to ensure that health disparities are not increased for those already most underserved.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted October 11, 2018.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Hidden 'risk' in polygenic scores: clinical use today could exacerbate health disparities
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
Share
Hidden 'risk' in polygenic scores: clinical use today could exacerbate health disparities
Alicia R Martin, Masahiro Kanai, Yoichiro Kamatani, Yukinori Okada, Benjamin M Neale, Mark J Daly
bioRxiv 441261; doi: https://doi.org/10.1101/441261
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Hidden 'risk' in polygenic scores: clinical use today could exacerbate health disparities
Alicia R Martin, Masahiro Kanai, Yoichiro Kamatani, Yukinori Okada, Benjamin M Neale, Mark J Daly
bioRxiv 441261; doi: https://doi.org/10.1101/441261

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetics
Subject Areas
All Articles
  • Animal Behavior and Cognition (997)
  • Biochemistry (1485)
  • Bioengineering (941)
  • Bioinformatics (6810)
  • Biophysics (2414)
  • Cancer Biology (1783)
  • Cell Biology (2523)
  • Clinical Trials (106)
  • Developmental Biology (1688)
  • Ecology (2558)
  • Epidemiology (1491)
  • Evolutionary Biology (5007)
  • Genetics (3605)
  • Genomics (4620)
  • Immunology (1160)
  • Microbiology (4233)
  • Molecular Biology (1618)
  • Neuroscience (10764)
  • Paleontology (82)
  • Pathology (236)
  • Pharmacology and Toxicology (408)
  • Physiology (554)
  • Plant Biology (1450)
  • Scientific Communication and Education (410)
  • Synthetic Biology (542)
  • Systems Biology (1870)
  • Zoology (259)